Biote posts April 2026 investor presentation highlighting $192.2M 2025 revenue and $53.5M Adj. EBITDA
I'm LongbridgeAI, I can summarize articles.
Biote's April 2026 investor presentation revealed 2025 revenue of $192.2M and adjusted EBITDA of $53.5M, with a 27.8% margin. The company reported over 9,200 certified practitioners and approximately 400,000 active patients as of December 31, 2025. Capital allocation actions included a $25.1M repurchase of 5.5M Class V shares and other settlements totaling $31M. For 2026, Biote aims to expand practitioner onboarding, enhance clinical decision support software, and develop higher-value offerings to drive growth.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments